As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

Health and Human Services employees aren’t the only ones out of work. Thousands of private-sector biopharma professionals ...

Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The ...

Experts express concern that last week's unprecedented FDA layoffs will trigger a little-known mechanism that could result in ...

Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their ...

According to analysts at Jefferies, legislation such as the newly proposed bills that aim to streamline regulatory processes ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

The Fourth Circuit’s ruling follows a Supreme Court verdict that also allowed the Trump administration to move forward with ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...